Thyroidectomy with versus without radioiodine in patients with low-risk thyroid cancer
Dr. Sophie Leboulleux
In patients with low-risk differentiated thyroid cancer undergoing thyroidectomy, the postoperative administration of radioiodine is controversial. The multicenter phase 3 ESTIMABL2 trial in France found that in patients with low-risk thyroid cancer undergoing thyroidectomy, a follow-up strategy that did not involve the use of radioiodine was noninferior to an ablation strategy with radioiodine in terms of occurrence of functional, structural, and biologic events at 3 years (quick take video summary).
